WuXi Biologics has completed the topping out of its new Drug Product facility at its Singapore CRDMO Hub, set to begin operations in 2027. The facility will produce about 100 million pre-filled syringes and vials annually, enhancing WuXi's manufacturing capacity by 120,000 liters. Located in Tuas Biomedical Park, the site features advanced manufacturing lines and green technologies, reinforcing Singapore's role as a biopharmaceutical hub. This expansion supports WuXi's global network and commitment to sustainable, high-quality biologics manufacturing.
US stock futures fell slightly with Dow futures down 62 points, reflecting investor caution amid ongoing geopolitical risks involving Iran. President Donald Trump expressed openness to direct talks with Iran's Supreme Leader Ayatollah Khamenei if dip...
A class action lawsuit has been filed against zSpace, Inc. by Robbins LLP on behalf of investors who bought shares during the company's December 2024 IPO. The lawsuit alleges that zSpace misled investors by failing to disclose key financial and legal...
Wescan Goldfields Inc. has closed the first tranche of its private placement, raising $2.24 million by issuing over 10 million units at $0.22 each. Each unit includes one common share and half a warrant to buy more shares at $0.35 within two years. T...
In recognition of National Homeownership Month, First Federal Savings Bank and the Independent Community Bankers of America (ICBA) are advising prospective homebuyers to work with local community banks for guidance. They emphasize steps like securing...
Verizon Communications announced a quarterly dividend of 70.75 cents per share, maintaining the same rate as the previous quarter. The dividend will be paid on August 3, 2026, to shareholders recorded by July 10, 2026. Verizon highlighted its 20 cons...
